A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types

ConclusionThis popPK analysis showed cabozantinib CL/F values to be higher for patients with MTC and may account for the higher dosage required in this patient population (140-mg) to achieve plasma exposures comparable to those in patients with RCC and other tumor types administered a 60-mg cabozantinib tablet dose. Possible factors that may underlie the higher cabozantinib clearance observed in MTC patients are discussed.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research